Previous Article | Next Article 
Journal of Virology, December 2001, p. 11641-11650, Vol. 75, No. 23
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.23.11641-11650.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Gene Expression Profile of Herpesvirus-Infected T
Cells Obtained Using Immunomicroarrays: Induction of
Proinflammatory Mechanisms
Michael
Mayne,1,*
Chris
Cheadle,2
Samantha S.
Soldan,3,4
Claudio
Cermelli,3,5
Yoshihisa
Yamano,3
Nahid
Akhyani,3
Jim E.
Nagel,2
Dennis D.
Taub,2
Kevin G.
Becker,2 and
Steven
Jacobson3
Department of Pharmacology and Therapeutics,
University of Manitoba, Winnipeg, Manitoba,
Canada1; Microarray Unit, National
Institute on Aging, National Institutes of Health,
Baltimore,2 and Viral Immunology Branch,
National Institute of Neurological Disorders and Stroke, National
Institutes of Health, Bethesda,3 Maryland;
Institute of Biomedical Sciences, Department of Genetics,
George Washington University, Washington, D.C.4;
and Department of Hygiene, Microbiology and Biostatistics,
University of Modena and Reggio Emilia, Modena,
Italy5
Received 25 May 2001/Accepted 28 August 2001
 |
ABSTRACT |
Herpesvirus infections can frequently lead to acute inflammation,
yet the mechanisms regulating this event remain poorly understood. In
order to determine some of the immunological mechanisms regulated by
human herpesvirus infections, we studied the gene expression profile of
lymphocytes infected with human herpesvirus 6 (HHV-6) by using a novel
immunomicroarray. Our nylon-based immunomicroarray contained more than
1,150 immune response-related genes and was highly consistent between
experiments. Experimentally, we found that independently of the HHV-6
strain used to infect T cells, multiple proinflammatory genes were
increased and anti-inflammatory genes were decreased at the mRNA and
protein levels. HHV-6 strains A and B increased expression of the genes
for interleukin-18 (IL-18), the IL-2 receptor, members of the tumor
necrosis factor alpha superfamily receptors, mitogen-activated protein
kinase, and Janus kinase signaling proteins. As reported
previously, CD4 protein levels were also increased significantly.
Specific type 2 cytokines, including IL-10, its receptor, and IL-14,
were downregulated by HHV-6 infection and, interestingly, amyloid
precursor proteins and type 1 and 2 presenilins. Thus, T cells respond
to HHV-6 infection by inducing a type 1 immune response that may play a
significant role in the development and progression of diseases
associated with HHV-6, including pediatric, hematologic, transplant,
and neurologic disorders.
 |
INTRODUCTION |
Human herpesvirus 6 (HHV-6) is a
lymphotropic betaherpesvirus first isolated from the peripheral blood
of immunocompromised patients with lymphoproliferative disorders
(34). Infection with HHV-6 typically occurs before the age
of 3 years, and primary infection can account for 10 to 40% of the
hospitalizations of children in this age group. HHV-6 is a clinically
relevant virus and is the causative agent of exanthem subitum, a
pediatric fever and skin rash (roseola) (47) that can have
serious and fatal complications (5). The seroprevalence of
HHV-6 in the general population is greater than 90% (10,
15), its reactivation is common in immunocompromised
individuals, and, like the closely related virus cytomegalovirus (CMV),
it has been associated with organ, bone marrow, and peripheral blood
cell transplantation failure and engraftment inhibition (for reviews,
see references 1 and 48). HHV-6 infection may
also enhance human immunodeficiency virus (HIV) replication and has
been suggested to play a role in HIV/AIDS progression (13,
24).
In addition to its role in pediatric febrile illness and
transplantation, HHV-6 infection has also been associated with central nervous system (CNS) complications, including neuroinflammation, febrile seizures, and encephalitis/encephalopathy (48). In
immunocompetent adults, HHV-6 is considered a commensal virus of the
CNS (8, 14). However, HHV-6 has been linked with the
pathogenesis of two chronic progressive demyelinating diseases of the
CNS, multiple sclerosis (MS) and progressive multifocal
leukoencephalopathy (8). The findings in MS are based on
immunological, molecular, and histological studies (2, 3, 8, 12,
17, 29, 35, 40, 42). Despite the association of HHV-6 with these clinical disorders, the pathological mechanisms and functional responses of cells infected with HHV-6 have yet to be defined. The
virus/host interaction studies that are currently being done include
analyses of viral variants, genetic susceptibility loci, and
virus-specific immune responses (41).
Two major viral subgroups of HHV-6 have been defined, and they are
designated variants A and B. Although there is significant DNA sequence
homology between the two variants, each has distinctive genomic,
antigenic, and biological properties (1, 6, 30). HHV-6B is
found primarily in the peripheral blood, saliva, and lymph nodes of
healthy individuals and has been detected in the serum of children with
roseola (47). HHV-6A is detected less frequently than
HHV-6B in healthy adults and appears primarily in the skin, brain, and
cerebrospinal fluid. Little is known about the epidemiological and
geographical distribution of the HHV-6A variant (13). A
greater neurotropism of the HHV-6A variant has been suggested based on
the detection of HHV-6A in the cerebrospinal fluid of children and
adults (20). In addition, HHV-6A has been demonstrated in
the CNSs of AIDS patients with areas of demyelination (8).
Increased HHV-6A-specific immune responses and the detection of
HHV-6A-specific DNA sequences in the serum, urine, and peripheral blood
lymphocytes of MS patients support an involvement of the HHV-6A variant
in this disorder (3, 23, 42).
Although herpesvirus infections can induce proinflammation and, in
acute cases, cause neuroinflammation or become fatal (33, 48), relatively little is known about the basic biology of this betaherpesvirus and how it regulates the immune response. To determine immunologically related cellular responses to HHV-6 infection, the gene
expression profile of HHV-6-infected T cells was evaluated by using a
novel immunomicroarray system. This custom human immunomicroarray was
composed almost entirely of known gene sequences that were selected
from the human cDNA library from Research Genetics. The immunomicroarray consisted of interleukin ligands and receptors, chemokines, and cellular signaling molecules. An entire listing of the
array can be found at www.grc.nia.nih.gov/branches/rrb/dna/dna.htm. We have also posted the raw data from these experiments and our analysis of HHV-induced changes in T-cell gene expression at
www.sbrc.mb.ca/dnnd. It is demonstrated here that, independently of the
HHV-6 variant studied, HHV-6 induces the gene expression and protein
production of multiple proinflammatory molecules, in particular, IL-18
and CD4. In contrast, IL-10 and IL-14, specific chemokine receptors and
members of the presenilin and amyloid beta processing pathway, were
downregulated. HHV-6 variant-specific gene expression profiles were
also identified. These results suggest that T cells infected with HHV-6
induce proinflammatory mechanisms and highlight the use of molecular
profiling of virus-infected cells as a powerful tool with which to
define novel mechanisms of virus/host cell interactions.
 |
MATERIALS AND METHODS |
Cell lines, HHV-6, and CPE.
The human T-cell lymphoblast
line SupT1 was used to propagate the HHV-6A variant (GS) and the HHV-6B
variant (Z29). SupT1 cell culture conditions and input multiplicity of
infection were previously determined for the HHV-6A and HHV-6B
variants, and infected and uninfected cell cultures (5 × 105 cells/ml) were prepared as previously
described (42). Approximately 7 days following passage of
cells, cytopathic effects (CPE) were observed and fresh uninfected
cells were added at an infected-uninfected cell ratio of 1:2. Infection
of the SupT1 cell line by HHV-6 was confirmed by immunofluorescence
assay (IFA; see below). Infected and uninfected cells were harvested 5 days after passage. Greater than 50% of the infected SupT1 cells
exhibited CPE and were positive by IFA staining on the day of harvest.
HHV-6-infected and uninfected cells (5 × 107) were washed with phosphate-buffered saline
(PBS), pH 7.2; cells were centrifuged at 600 × g; and
pellets were frozen at
80°C and used for total RNA isolation.
Supernatants were also harvested after centrifugation at 600 × g for 10 min.
Real-time quantitative PCR and analysis of HHV-6 DNA and
RNA.
The primer set used for amplification of the DNA encoding the
major capsid protein of HHV-6 was 5'-CTGCAGCAAATACGTTCTAGCC-3' (positions 102793 to 102772) and 5'-GTGACGAGCGTTATTCCTTCG-3'
(positions 102656 to 102676), yielding a product of 520 bp. The
probe for HHV-6 was 5'-TGCCGCTCTGGATAATTTGGCTTTGTC-3'
(positions 102718 to 102744). Standard control was used as
described previously (37). The primer set for
-actin as
an internal calibration was 5'-CACACTGTGCCCATCTACGA-3'
(positions 2146 to 2165) and
5'-CTCAGTGAGGATCTTCATGAGGTAGT-3' (positions 2250 to 2225).
The probe for
-actin was 5'-ATGCCCTCC-CCCATGCCATCCTGCGT-3' (positions 2171 to 2196). A standard curve for HHV-6 was
generated by using serially 10-fold-diluted viral DNA
(106 to 102 copies) that
was purified from HHV-6B (Z29)-infected SupT1 cells. A standard curve
for
-actin was generated following twofold serial dilution of
genomic DNA purified from normal donor peripheral blood mononuclear
cells (approximately 8 × 105 to 5 × 104 copies). Because individual peripheral blood
mononuclear cells have two copies of
-actin, 1 ng of DNA contains
approximately 333 copies of the gene for
-actin. Five hundred
nanograms of sample DNA was used as the template and analyzed with an
ABI Prism 7700 Sequence Detection System (Applied Biosystems).
Amplification of standard and sample DNAs was conducted in the same
96-well reaction plate (Applied Biosystems) by using 50°C for 2 min
for activation of uracil-N-glycosylase, 95°C for 10 min in
order to inactivate uracil-N-glycosylase, and 45 cycles of
95°C for 15 s (denaturation) and 60°C for 1 min (annealing and
extension). All standards and samples were assayed in triplicate.
IFA.
For the preparation of slides, infected cells showing a
viral CPE were collected by centrifugation, washed twice with sterile PBS, and fixed on glass slides with acetone for 5 min at
20°C. Fixed slides were incubated with a 1:40 dilution of a mouse monoclonal antibody (MAb) against HHV-6 glycoprotein 116/64/54 (gp116/64/54; ABI,
Columbia, Md.) for 30 min at 37°C. The slides were washed three times
in PBS for 10 min and twice with distilled water and incubated with
fluorescein-labeled goat anti-mouse immunoglobulin G serum (Sigma, St.
Louis, Mo.) for 30 min at 37°C and washed as described above. Slides
were stained with Evans blue at a 1:40 dilution, washed once with
distilled water, and mounted with buffered glycerin. Uninfected SupT1
cells were used as negative controls.
NIA immunomicroarray.
A defined set of 1,152 immune
response-related cDNAs was PCR amplified and printed on nylon filters
by using a GMS417 Microarrayer (Genetic Microsystems). Clones were
selected from a commercially available (Research Genetics, Inc.) master
set of approximately 15,000 human, verified-sequence, T1 phage-negative
IMAGE Consortium clones. A small number of clones were acquired
privately. The nylon membrane-based assays use a relatively small
quantity of total RNA as a probe (100 to 1,000 ng) compared to
fluorescent cDNA assays conducted using glass microarray slides. The
National Institute on Aging (NIA) immunomicroarray includes cDNAs
encoding immune response-specific cell differentiation antigens;
cytokines and their receptors, including interferons, interleukins, and chemokines; apoptosis-related genes; structural and cytoskeletal genes;
and signal transduction genes, including those for Janus kinase
signaling protein (JAK), STATs, transcription factors, growth
factors, and other cellular and metabolic molecules. An entire
list of the genes printed on the immunomicroarray can be found at
www.grc.nia.nih.gov/branches/rrb/dna/dna.htm. The raw data and Z
ratios calculated in these experiments can be found at
www.sbrc.mb.ca/dnnd.
RNA preparation and microarray analysis.
Total RNA was
prepared from infected SupT1 cells by using SNAP RNA isolation kits
(Invitrogen), and RNA integrity was confirmed by 1.1% agarose
formaldehyde gel electrophoresis. One microgram of total RNA was primed
by using oligo (dT) oligonucleotide (Research Genetics), and the
first-strand cDNA probe was labeled with
-33P
(3,000 Ci/mmol; ICN) in the presence of a final concentration of 1×
first-strand cDNA buffer, 0.1 M dithiothreitol, 0.5 mM deoxynucleoside triphosphates minus dCTP (Pharmacia), RNase inhibitor (10 IU; Life
Technologies), and 1 U of Superscript 2 reverse transcriptase (Life
Technologies). The reaction was incubated for 70 min at 42°C, and RNA
was removed by using a Biospin P30 spin column (Bio-Rad) following
addition of 50 mM EDTA and 200 nM NaOH and incubation at 65°C for 30 min. Radioisotope incorporation was determined by counting a 1-µl
sample, and 75 µl of each probe was denatured and added to an
immunomicroarray that had been pretreated for 4 h at 50°C with
microhybridization buffer (Research Genetics). Hybridization continued
overnight at 50°C, and microarrays were washed in 1× SSC (1× SSC is
0.15 M sodium citrate plus 0.015 M sodium citrate)-0.1% sodium
dodecyl sulfate for 3 × 15 min at 50°C. Arrays were exposed to
phosphorimaging sheets (Storm) for 48 h and analyzed with a Storm
PhosphorImager (Molecular Dynamics). All genes produced a quantifiable
signal following hybridization.
Gene expression was determined from microarray experiments by capturing
the pixel density of each 33P-labeled PCR product
(gene) by using QuantOne Image Software (Bio-Rad) and exporting the
resulting data to Microsoft Excel (Microsoft, Seattle, Wash.). Raw
intensity data for each experiment was normalized by Z transformation.
Briefly, first the raw pixel density data for each gene is
log10 transformed and then Z scores are
calculated. Z scores are calculated by subtracting the average gene
intensity (calculated from the sum of all data points) from the log
intensity value of each gene and dividing that result by the standard
deviation of all of the measured intensities. Thus, Z scores transform
raw intensity data into a more flexible data expression in which the
value of each individual gene is reported as a function of its distance
from the mean of all of the measured gene intensities and is expressed
in units of standard deviation. This flexible normalization
procedure facilitates comparisons between microarray experiments by
adjusting for differences in hybridization intensity. Z scores were
exported and directly subjected to Cluster analysis (16)
(Stanford University).
Gene expression differences between any two experiments are calculated
by taking the difference between the observed gene Z scores. Z ratios
express these differences in terms of their relationship to the
standard deviation of the distribution of all of the observed gene
changes. All of the calculated Z ratios for a given comparison can be
rank ordered on this basis. Z ratios were determined for all of the
individual genes in the appropriate comparisons; for example, a Z ratio
for IL-18 would be calculated by determining the ratio of the IL-18 Z
scores obtained from uninfected and HHV-6-infected SupT1 cells.
ELISA and immunoblot analysis.
Cell culture supernatants
were collected and centrifuged at 600 × g for 10 min.
IL-18 and IL-10 protein levels were determined with an enzyme-linked
immunosorbent assay (ELISA) in accordance with the manufacturer's (R&D
Systems, Minneapolis, Minn.) suggestions. Western blot analysis for CD4
was performed by using approximately 5 × 106 HHV-6A-infected, HHV-6B-infected, and
uninfected T cells that were harvested 5 days after passage by
centrifugation at 600 × g for 10 min. Cell
supernatants were discarded, and the remaining cell pellets were lysed
in 500 µl of radioimmunoprecipitation assay buffer (50 mM NaCl, 1%
NP-40, 0.5% deoxycholic acid, 50 mM Tris [pH 7.4], 1 mM EGTA, 10 mM
Na orthovanadate, 10 mM NaF, and protease inhibitor cocktail [one
tablet per 50 ml; Sigma]) for 10 min at 4°C. Each sample was
centrifuged at 14,000 × g for 10 min at 4°C, and
protein levels in cell lysates were determined (Pierce, Rockford,
Ill.). Whole-cell lysates obtained from HHV-6-infected and uninfected
cells were mixed with an equal amount of 2× sample buffer (0.125 M
Tris, 4% sodium dodecyl sulfate, 20% [vol/vol] glycerol, 0.01%
[wt/vol] bromophenol blue, 10% 2-mercaptoethanol) and boiled for 5 min. Cell lysates (50 µg) were separated and resolved by using a 10%
Tris-glycine gel (Invitrogen, Carlsbad, Calif.) and transferred to a
0.22-µm-pore-size nitrocellulose membrane (Schleicher & Schuell,
Keene, N.H.), and Western analysis was performed with an anti-CD4 MAb
(1:1,000; R&D Systems) or the housekeeping protein vinculin (1:1,000
dilution; Sigma). Proteins were visualized with horseradish
peroxidase-conjugated anti-mouse immunoglobulin G antibody (Santa Cruz
Biotechnology, Santa Cruz, Calif.) at a 1:30,000 dilution and
subsequent detection by enhanced-chemiluminescence assay (Pierce). The
Kodak (Rochester, N.Y.) Image Station 440 was used to estimate the net
intensities of visualized bands.
Cluster analysis and statistics.
Clustering of changes in
gene expression was determined by using public domain Cluster based on
pairwise average-linkage cluster analysis (16). Gene
expression raw data, log values, and Z scores were averaged by using
the mean ± the standard deviation. Comparisons between
experiments were conducted by regression analysis. For all tests,
statistical significance was considered to be at the P < 0.05 level (Instat2; GraphPad Software, San Diego, Calif.).
 |
RESULTS |
Variants HHV-6A and HHV-6B infect SupT1 cells with equal
efficiency.
The T-cell lymphoblast line SupT1 was infected with
the HHV-6A (GS) and HHV-6B (Z29) variants to define virus-induced
molecular profiles by using immunomicroarrays. Because the level of
virus expression may influence molecular profiling of virus-infected cells, it was critical to demonstrate that comparable levels of infection with the HHV-6A and HHV-6B variants were attained. This was
demonstrated in the following ways. (i) The percentage of large,
balloon-shaped cells, as a measure of CPE observed in HHV-6A- and
HHV-6B-infected cultures, was equivalent with each infection showing
approximately 50% ± 7% CPE (11) (Fig.
1A). (ii) The percentage of cells
expressing HHV-6 antigens, as defined by IFA with the gp116/54/64 MAb
(Advanced Biotechnologies Inc., Columbia, Md.), which detects both
variants of HHV-6, was similar (approximately 50% ± 5%; Fig. 1B).
(iii) Quantitative TaqMan analysis of HHV-6 DNA confirmed equivalent
HHV-6 viral loads in infected T cells (Fig. 1C). No HHV-6 DNA was
amplified from uninfected T cells, while T cells infected with the
HHV-6A and HHV-6B variants were infected at averages of 10 and 11 copies per cell, respectively (Fig. 1C). These results were obtained in
samples from cell lines harvested for all microarray experiments (Fig.
1C). (iv) Finally, semiquantitative reverse transcription-PCR analysis
of HHV-6-infected T cells showed that mRNA encoding a late-expression
HHV-6 viral chemokine gene (U83) (49) was readily detected
(Fig. 1D).

View larger version (65K):
[in this window]
[in a new window]
|
FIG. 1.
SupT1 cells are highly infected with HHV-6A or HHV-6B.
(A) CPE at 5 days following infection with HHV-6A or HHV-6B. Large,
balloon-shaped cells were abundant (approximately 50% ± 7% of the
total cell number) in SupT1 cultures infected with either HHV-6A or
HHV-6B. HHV-6B induced a slightly greater individual CPE than did
HHV-6A (magnification, ×32). (B) SupT1 cells were infected with HHV-6A
or HHV-6B, and 5 days following infection, cells were fixed and stained
with an HHV-6 anti-gp116/64/54 MAb. Fluorescence imaging shows that a
high percentage (approximately 50% ± 5%) of SupT1 cells were
infected with HHV-6A or HHV-6B (magnification, ×20). (C) TaqMan
analysis determined that the HHV-6A and HHV-6B genomes were present at
approximately 10 copies per T cell. (D) Semiquantitative reverse
transcription-PCR determined that the HHV-6 U83 gene was expressed in
SupT1 cells infected with either HHV-6A or HHV-6B. Because U83 is a
late-expression gene, this result shows that HHV-6A or HHV-6B
replication occurs in SupT1 cells. The data shown are representative of
three independent infections. Con, control.
|
|
Consistency between immunomicroarray analyses.
It was
important to compare mRNA populations from uninfected and
HHV-6-infected T cells to determine interassay variability. To correct
for interassay variability (hybridization intensity), gene expression
profiles were normalized for each microarray by determining Z scores.
The Z score represents the average change in gene expression from the
mean hybridization value of each microarray (for a full description,
see Materials and Methods). As shown in Fig.
2A, hybridization intensities between
microarray experiments and gene expression profiles were highly
consistent between experiments. Moreover, assignment of color channels
for independent experimental conditions highlighted significant changes
in gene expression (Fig. 2A). Results of regression analysis of Z
scores of gene expression profiles from control experiments ranged from
r = 0.84 to r = 0.86 with Z scores
ranging from 5.5 to
3.9, ranged from r = 0.79 to
r = 0.85 in T cells infected with variant A with Z scores ranging from 6.7 to
4.1, and ranged from r = 0.76 to r = 0.84 in T cells infected with variant B
with Z scores ranging from 8.1 to
4.6. For all experiments, the
Pearson correlation average was P = 0.83. An example of
a Z score regression analysis from uninfected and HHV-6-infected T
cells is shown in Fig. 2. These results demonstrate the reliability of
immunomicroarray analysis from HHV-6-infected cells. In order to
further examine microarray reliability, we conducted cluster analysis
(16). Importantly, clustering of Z scores confirmed that
similar experiments clustered together, indicating reliability in the
microarray analysis of the gene expression profiles across experiments
(Fig. 3).

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 2.
Immunomicroarray analysis was consistent between
experiments. (A) Representative radiolabeled nylon immunomicroarray
showing hybridization patterns of mRNA populations from uninfected and
HHV-6A-infected SupT1 cells and a false color overlay comparing changes
in gene expression from uninfected cells (green channel) and SupT1
cells infected with HHV-6A (red channel). Yellow represents genes that
were expressed at equal intensities. Each array contains two identical
grids. (B and C) Regression analysis of Z scores from two independent
experiments showing that the microarray hybridization patterns are
highly similar. Z scores representing individual genes from each
experiment were plotted, and the relationship (slope) between two
independent experiments was calculated. A perfect relationship between
experiments would equal a slope of 1. The average Pearson correlation
for all experiments was P = 0.83 ± 0.10.
|
|

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 3.
Gene expression profiles were highly similar between
independent experiments and experimental conditions clustered together.
Z scores ranging from 5 to +5 were subjected to Cluster analysis,
which determined that a wide array of gene expression profiles was
present between uninfected and HHV-6-infected SupT1 cells. An example
of genes that were upregulated or downregulated is enlarged and shown
at the right. Importantly, experimental conditions also clustered
together, demonstrating the reliability of microarray
analysis.
|
|
HHV-6 infection induces multiple changes in gene expression.
Immunomicroarray gene expression profiles were determined from HHV-6A-
and HHV-6B-infected T cells and compared to that of uninfected cells. Z
ratios were calculated by comparing Z scores from individual
experiments. As shown in Table 1, a
number of genes were increased or decreased at the mRNA level by
at least 2 Z ratios in HHV-6-infected cells. For example,
phosphofructokinase, which is important in energy metabolism; members
of the JAK kinase signaling cascade; and HLA class 1 and 2 genes, which
are important in antigen presentation, were all increased. Not shown
are members of the apoptosis family that were highly induced
independently of the HHV-6 variant used to infect SupT1 cells. In
particular, apoptosis-associated tyrosine kinase (accession number
ABI014541) was induced by 3.84 and 3.27 (Z ratio) in HHV-6B- and
HHV-6A-infected T cells, respectively. In addition, caspases 3 and 8 were elevated independently of the variant used to infect T cells
(not shown), suggesting that SupT1 cells undergo apoptosis during
infection. Genes that were downregulated by at least 2 Z ratios during
infection included members of the presenilin and amyloid beta precursor protein family and the recently identified measles receptor signaling lymphocytic activation molecule (SLAM; CDw150) (43; Table
1).
HHV-6 infection of SupT1 cells induces proinflammatory and
decreases anti-inflammatory gene expression.
Several
proinflammatory genes showed increased mRNA levels, including IL-18,
IL-2 receptor, mitogen-activated protein kinase family members, tumor
necrosis factor (TNF) receptor superfamily members, and associated
signaling molecules, including TRAF3 and CD4 (Table
2). Interestingly, the majority of the
mRNA levels for proinflammatory interleukins, including IL-1, IL-8, and
IL-12, their receptors, and gamma interferon (IFN-
) were unchanged
during HHV-6 infection, independently of the variant used (data not
shown). Associated with increased expression in specific
proinflammatory genes was the concurrent downregulation of the
anti-inflammatory genes for IL-10 and its receptor, the IL-13 receptor,
and IL-14. All of these genes are important in reducing proinflammatory
cytokine synthesis (Table 2). Only reported here are genes whose
expression profiles were modified by at least 1.5-fold. A full listing
of the raw data, Z scores, and Z ratios of these experiments can be
located at www.sbrc.mb.ca/dnnd.
HHV-6 variant-specific changes in gene expression.
As variants
HHV-6A and HHV-6B differ at the molecular, immunological, and tropic
levels (9, 21), immunomicroarray analysis also
demonstrated differential expression of several genes in T cells
infected with either HHV-6A or HHV-6B (Table
3). When gene expression profiles were
compared between the virus variants, HHV-6B-infected T cells had
elevated levels of several proinflammatory molecules compared to
HHV-6A-infected cells, including members of the TNF-
and lymphotoxin
receptor superfamily, phospholipase C, and specific adhesion molecules,
including CD28 relative to HHV-6A (Table 3). Compared to
HHV-6B-infected T cells, HHV-6A-infected T cells elevated the
expression of the gene for phospholipase D2 (2.48-fold [Z ratio]
higher than in HHV-6B-infected SupT1 cells), NF-
B-inducing kinase
(2.04-fold higher than in HHV-6A-infected cells), nitrogen oxide
synthase (2.02-fold higher than in HHV-6B-infected cells), and
JAK-1 (1.75-fold higher than in HHV-6A-infected cells).
Pro- and anti-inflammatory cytokine protein levels in
HHV-6-infected SupT1 cells.
In agreement with microarray analysis
results, IL-18 protein levels were elevated significantly in
supernatants from HHV-6A- and HHV-6B-infected T-cell cultures (Fig.
4C). IL-18 mRNA levels were increased by
approximately 2 Z ratios, independently of the HHV-6 variant analyzed;
however, IL-18 protein levels were approximately fivefold higher in
supernatants from SupT1 cell cultures infected with HHV-6B than in
those infected with HHV-6A. Because IL-18 levels were elevated
significantly in supernatants from infected cells, we chose to analyze
other proinflammatory cytokines, including IFN-
and IL-6, although
their mRNA levels did not change during HHV-6 infection. Although
IFN-
protein levels did not change during HHV-6 infection, IL-6
levels were elevated significantly. T cells infected with HHV-6A had
14 ± 8 pg/ml (P < 0.01), and T cells infected
with HHV-6B had 10 ± 2 pg/ml (P < 0.01). IL-6 was not detected in uninfected cells. We further examined the TH1-type
response of T cells infected with HHV-6 by examining the levels of the
anti-inflammatory cytokine IL-10, a cytokine that was downregulated by
HHV-6 infection (Table 2). In agreement with the microarray data, IL-10
protein levels decreased significantly in supernatants from T cells
infected with HHV-6A or HHV-6B (Fig. 4D). Although IL-10 mRNA was
detected in all of the samples and IL-10 protein levels were readily
detectable in uninfected cell culture supernatants, IL-10 protein could
not be detected in supernatants from T cells infected with HHV-6. These
results further indicate that HHV-6 infection induces proinflammatory
mechanisms and, importantly, confirm the reliability of using these
immunomicroarrays to determine functional changes in T cells infected
with HHV-6.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 4.
Protein levels mirror mRNA levels in uninfected and
HHV-6-infected SupT1 cells. (A) Whole-cell lysates were collected from
the uninfected and infected cells used for both microarray experiments.
Immunoblot analysis for CD4 and the housekeeping protein vinculin was
performed on uninfected (lanes 1 and 2), HHV-6A-infected (lanes 3 and
4), and HHV-6B-infected (lanes 5 and 6) whole-cell lysates. Lanes 1, 3, and 5 represent data from cells harvested for the first microarray
analysis, while lanes 2, 4, and 6 represent data from cells harvested
for the second microarray experiment. (B) CD4 expression was increased
1.74-fold ± 0.24-fold and 1.87-fold ± 0.17-fold in cells
infected with the HHV-6A and HHV-6B variants, respectively, compared to
that in uninfected SupT1 cells, as shown by densitometry. IL-18 (C) and
IL-10 (D) protein levels present in cell culture supernatants were
analyzed by ELISA. IL-18 protein levels increased and IL-10 protein
levels decreased during HHV-6A or HHV-6B infection, which is in
agreement with observed changes in mRNA expression. The data shown are
representative of two independent experiments. **,
P < 0.001.
|
|
 |
DISCUSSION |
Herpesvirus infections frequently activate an extensive immune
response that, in acute cases, can be fatal (13, 33).
However, the biological events that regulate the development of
proinflammatory responses to herpesvirus infection remain poorly
understood. This report focuses on HHV-6, a virus that has been
associated with inflammatory disorders in pediatric and transplant
patients and, more recently, with chronic progressive neurologic
disease (39, 48). To further understand the mechanisms by
which HHV-6 regulates a variety of immune mechanisms, a microarray
analysis was performed on a large panel of genes involved with the
human immune response. The NIA immunomicroarray was designed to include
a wide assortment of pro- and anti-inflammatory cytokines, chemokines,
and their receptors, as well as specific signaling molecules, including tyrosine kinases, protein kinase C, phospholipase C, and
dephosphorylating phosphatases. The use of a focused array comprising
known gene sets allowed a targeted survey of virus-specific immune
responses in human T cells infected with HHV-6. We chose to study
the immortalized SupT1 cell line because these cells were adapted
previously to culture HHV-6A and HHV-6B, and thus, we could
compare the HHV-6 variant-specific actions within one cell line.
Primary human T cells would also provide an excellent model; however,
multiplicity of infection would vary between T-cell populations and
changes in gene expression between clinical specimens would further
complicate microarray analysis.
The use of our novel immunomicroarray was a valid and reproducible
approach, as demonstrated by a number of experimental observations. The
intra- and interassay variability was remarkably consistent from RNAs
obtained from independent HHV-6-infected and uninfected T cells (Fig.
2). Altered expression of several genes identified by this approach
(Table 1) was consistent with known properties of T cells infected with
HHV-6. For example, one of the highest Z ratios for both HHV-6A- and
HHV-6B-infected T cells (Z ratio = 2.5; Table 2) was for CD4 mRNA.
In agreement with these results, a significant increase in CD4 protein
levels was reported previously for HHV-6-infected T cells
(26) and confirmed in this study by Western analysis (Fig.
4A). The function of HHV-6-induced upregulation of CD4 remains unclear
because HHV-6 uses CD46 as its primary receptor (36).
Several genes were found to be downregulated by HHV-6 infection,
according to immunomicroarray analysis (Table 1). Although it was not
the focus of this study, it is of interest that SLAM was downregulated
significantly by HHV-6 (Z ratio =
2.25; Table 1). SLAM was
identified recently as the coreceptor for measles virus
(43), which, along with HHV-6, also uses CD46 as an entry
receptor. CD46 was originally defined as a receptor for HHV-6 through
the observation that CD46 is markedly downregulated during the course
of HHV-6 infection (36). Therefore, the downregulation of
SLAM, as identified by immunomicroarray analysis, suggests a possible
role for SLAM as a coreceptor for HHV-6.
Of particular interest to this study is the observation that a number
of proinflammatory genes were upregulated by HHV-6 infection while
several anti-inflammatory genes were downregulated (Table 2). The
recently described lymphokine IL-18 was identified by the
immunomicroarray as upregulated in cultures infected by both variants
of HHV-6 (Table1). IL-18, which was first identified as an
IFN-
-inducing agent in mice with endotoxic shock (28), increases IFN-
production independently of IL-12 and stimulates the
production of TH1-type cells (4). It is possible that
IL-18 elevation is an important part of innate immunity, as IL-18
levels are also elevated in macrophages infected with influenza A virus or Sendai virus (31). In support of the observed increase
in IL-18 mRNA as identified by immunomicroarray assay, IL-18 protein levels were demonstrated to be increased in supernatants of T cells
infected with HHV-6 (Fig. 4C). In T cells infected with the HHV-6B
variant Z29, the expression of IL-18 was increased approximately
fivefold compared with that in uninfected T cells (Fig. 4C). This
confirms the validity of the immunomicroarray data and suggests an
important role for IL-18 in HHV-6-mediated inflammation. An important
caveat of these studies is that microarray analysis of our in vitro
HHV-6 model, albeit highly reproducible, could not differentiate
between direct and indirect actions of HHV-6. This is particularly
evident for cytokine molecules that are released from T cells,
including IL-18. It is possible that most of IL-18 is released from
uninfected cells and, thus, the production of this proinflammatory
cytokine results from an indirect mechanism of HHV-6. In contrast, it
is possible that the majority of IL-18 is released from infected cells.
Regardless, HHV-6 infection of T cells elevates the gene for IL-18 and
other proinflammatory genes that would affect the local cellular
environment during HHV-6 replication. Finally, although the infection
efficiency was approximately 50%, the microarray analysis may not have
identified genes that were modestly affected (a Z ratio change of
<1.5).
As HHV-6 is currently under investigation as a possible etiologic agent
in MS (13), it is of interest that IL-18 is expressed in
demyelinating lesions of MS brains (7) and that levels of caspase 1, the regulatory enzyme of pro-IL-18, are elevated in the
peripheral blood of MS patients (18, 19). These studies suggest that activation of the IL-18 pathway may be involved in the
development of this demyelinating disease. Therefore, the increase in
IL-18 expression regulated by HHV-6 as demonstrated by immunomicroarray
analysis may be clinically relevant in this autoimmune disorder. HHV-6
has been associated with other diseases that target the immune system
and have pathological implications for the CNS, including HIV
(24). Specifically, HHV-6 infection enhances HIV
replication in vitro (27) and may break the latency of HIV
(24). Because IL-18 stimulates HIV type 1 replication in
human monocytic cells (38), it would be of considerable
interest to know if an HHV-6-mediated increase in IL-18 regulates HIV replication.
The finding that IL-18 was increased in T cells infected with HHV-6
suggested that other proinflammatory signaling molecules may also be
increased. Indeed, immunomicroarray analysis demonstrated that
HHV-6-infected T cells have significant increases in the gene
expression of multiple signaling molecules associated with a
proinflammatory response, including the IL-2 receptor,
mitogen-activated protein kinase, phosphofructokinase, TNF
receptor-associated proteins, JAK binding proteins, and small inducible
cytokines (Table 1). Activation of proinflammatory signaling events and
specific proinflammatory molecules are frequent features of viral
infections (22, 25, 32, 46). It is of interest that IL-18
reduces the levels of IL-10 (44). High levels of IL-18 may
explain the observed decrease in IL-10 levels in this study (Table 2
and Fig. 4D). IL-10 is an anti-inflammatory cytokine that inhibits the
production of several proinflammatory molecules, including IL-1 and
IL-12, and blocks the production of chemokines, including IL-8 and
MIP-1
(45). Because IL-18 and IL-10 play important pro-
and anti-inflammatory roles, respectively, these results suggest that
HHV-6 infection of T cells could promote a type 1 proinflammatory
cytokine response.
This study has demonstrated that pro and anti-inflammatory gene
expression in T cells is altered during HHV-6 infection. Use of a
defined immunomicroarray is a strategy that allows the targeted "mining" of information obtained from the analysis of changes in
gene expression within complete cellular mRNA populations. Importantly,
the upregulation of IL-18 mRNA was confirmed by protein analysis
of infected cell culture supernatants. Likewise, the downregulation of
IL-10 suggests that IL-18 and IL-10 work in concert as part of a
virus-induced cytokine-mediated mechanism involved in the pathogenesis
of diseases associated with HHV-6. As the list of HHV-6-associated
diseases expands, including pediatric, hematologic, transplant, and
neurologic disorders, mechanisms of virus-mediated pathogenesis need to
be characterized. The use of targeted immunomicroarray analysis will be
an important tool in the identification of genes and gene sets involved
in the host immune response to viral infections.
 |
ACKNOWLEDGMENTS |
This study was supported by the Manitoba Medical Service
Foundation and the Canadian Institutes of Health Research (M.M.), National Institutes of Health and National Institutes of Aging Intramural Funding Programs (S.J. and K.G.B.), and the Fondazione Cassa
di Risparmio di Carpi (C.C.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pharmacology and Therapeutics, University of Manitoba, R4050 St.
Boniface Hospital Research Centre, Winnipeg, Manitoba, Canada R2H 2A6. Phone: (204) 235-3942. Fax: (204) 237-4092. E-mail:
mmayne{at}cc.umanitoba.ca.
 |
REFERENCES |
| 1.
|
Ablashi, D. V.,
N. Balachandran,
S. F. Josephs,
C. L. Hung,
G. R. Krueger,
B. Kramarsky,
S. Z. Salahuddin, and R. C. Gallo.
1991.
Genomic polymorphism, growth properties, and immunologic variations in human herpesvirus-6 isolates.
Virology
184:545-552[CrossRef][Medline].
|
| 2.
|
Ablashi, D. V.,
W. Lapps,
M. Kaplan,
J. E. Whitman,
J. R. Richert, and G. R. Pearson.
1998.
Human herpesvirus-6 (HHV-6) infection in multiple sclerosis: a preliminary report.
Mult. Scler.
4:490-496[Abstract/Free Full Text].
|
| 3.
|
Akhyani, N.,
R. Berti,
M. B. Brennan,
S. S. Soldan,
J. M. Eaton,
H. F. McFarland, and S. Jacobson.
2000.
Tissue distribution and variant characterization of human herpesvirus (HHV)-6: increased prevalence of HHV-6A in patients with multiple sclerosis.
J. Infect. Dis.
182:1321-1325[CrossRef][Medline].
|
| 4.
|
Akira, S.
2000.
The role of IL-18 in innate immunity.
Curr. Opin. Immunol.
12:59-63[CrossRef][Medline].
|
| 5.
|
Asano, Y.,
T. Yoshikawa,
Y. Kajita,
R. Ogura,
S. Suga,
T. Yazaki,
T. Nakashima,
A. Yamada, and T. Kurata.
1992.
Fatal encephalitis/encephalopathy in primary human herpesvirus-6 infection.
Arch. Dis. Child.
67:1484-1485[Abstract].
|
| 6.
|
Aubin, J. T.,
H. Collandre,
D. Candotti,
D. Ingrand,
C. Rouzioux,
M. Burgard,
S. Richard,
J. M. Huraux, and H. Agut.
1991.
Several groups among human herpesvirus 6 strains can be distinguished by Southern blotting and polymerase chain reaction.
J. Clin. Microbiol.
29:367-372[Abstract/Free Full Text]. (Erratum, 30:2524.)
|
| 7.
|
Balashov, K. E.,
J. B. Rottman,
H. L. Weiner, and W. W. Hancock.
1999.
CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1 and IP-10 are expressed in demyelinating brain lesions.
Proc. Natl. Acad. Sci. USA
96:6873-6878[Abstract/Free Full Text].
|
| 8.
|
Blumberg, B. M.,
D. J. Mock,
J. M. Powers,
M. Ito,
J. G. Assouline,
J. V. Baker,
B. Chen, and A. D. Goodman.
2000.
The HHV6 paradox: ubiquitous commensal or insidious pathogen? A two-step in situ PCR approach.
J. Clin. Virol.
16:159-178[CrossRef][Medline].
|
| 9.
|
Braun, D. K.,
G. Dominguez, and P. E. Pellett.
1997.
Human herpesvirus 6.
Clin. Microbiol. Rev.
10:521-567[Abstract].
|
| 10.
|
Campadelli-Fiume, G.,
P. Mirandola, and L. Menotti.
1999.
Human herpesvirus 6: an emerging pathogen.
Emerg. Infect. Dis.
5:353-366[Medline].
|
| 11.
|
Cermelli, C.,
P. Pietrosemoli,
M. Meacci,
M. Pecorari,
A. M. Sabbatini,
B. Colombari, and M. Portolani.
1997.
SupT-1: a cell system suitable for an efficient propagation of both HHV-7 and HHV-6 variants A and B.
New Microbiol.
20:187-196[Medline].
|
| 12.
|
Challoner, P. B.,
K. T. Smith,
J. D. Parker,
D. L. MacLeod,
S. N. Coulter,
T. M. Rose,
E. R. Schultz,
J. L. Bennett,
R. L. Garber,
M. Chang, et al.
1995.
Plaque-associated expression of human herpesvirus 6 in multiple sclerosis.
Proc. Natl. Acad. Sci. USA
92:7440-7444[Abstract/Free Full Text].
|
| 13.
|
Clark, D. A.
2000.
Human herpesvirus 6.
Rev. Med. Virol.
10:155-173[CrossRef][Medline].
|
| 14.
|
Cuomo, L.,
P. Trivedi,
M. R. Cardillo,
F. M. Gagliardi,
A. Vecchione,
R. Caruso,
A. Calogero,
L. Frati,
A. Faggioni, and G. Ragona.
2001.
Human herpesvirus 6 infection in neoplastic and normal brain tissue.
J. Med. Virol.
63:45-51[CrossRef][Medline].
|
| 15.
|
Di Luca, D.,
P. Mirandola,
T. Ravaioli,
B. Bigoni, and E. Cassai.
1996.
Distribution of HHV-6 variants in human tissues.
Infect. Agents Dis.
5:203-214[Medline].
|
| 16.
|
Eisen, M. B.,
P. T. Spellman,
P. O. Brown, and D. Botstein.
1998.
Cluster analysis and display of genome-wide expression patterns.
Proc. Natl. Acad. Sci. USA
95:14863-14868[Abstract/Free Full Text].
|
| 17.
|
Friedman, J. E.,
M. J. Lyons,
G. Cu,
D. V. Ablashi,
J. E. Whitman,
M. Edgar,
M. Koskiniemi,
A. Vaheri, and J. B. Zabriskie.
1999.
The association of the human herpesvirus-6 and MS.
Mult. Scler.
5:355-362[Abstract/Free Full Text].
|
| 18.
|
Furlan, R.,
M. Filippi,
A. Bergami,
M. A. Rocca,
V. Martinelli,
P. L. Poliani,
L. M. Grimaldi,
G. Desina,
G. Comi, and G. Martino.
1999.
Peripheral levels of caspase-1 mRNA correlate with disease activity in patients with multiple sclerosis: a preliminary study.
J. Neurol. Neurosurg. Psychiatry
67:785-788[Abstract/Free Full Text].
|
| 19.
|
Furlan, R.,
G. Martino,
F. Galbiati,
P. L. Poliani,
S. Smiroldo,
A. Bergami,
G. Desina,
G. Comi,
R. Flavell,
M. S. Su, and L. Adorini.
1999.
Caspase-1 regulates the inflammatory process leading to autoimmune demyelination.
J. Immunol.
163:2403-2409[Abstract/Free Full Text].
|
| 20.
|
Hall, C. B.,
M. T. Caserta,
K. C. Schnabel,
C. Long,
L. G. Epstein,
R. A. Insel, and S. Dewhurst.
1998.
Persistence of human herpesvirus 6 according to site and variant: possible greater neurotropism of variant A.
Clin. Infect Dis.
26:132-137[Medline].
|
| 21.
|
Inoue, N.,
T. R. Dambaugh, and P. E. Pellett.
1993.
Molecular biology of human herpesviruses 6A and 6B.
Infect. Agents Dis.
2:343-360[Medline].
|
| 22.
|
Johnson, R. T.
1994.
The virology of demyelinating diseases.
Ann. Neurol.
36:S54-S60.
|
| 23.
|
Kim, J. S.,
K. S. Lee,
J. H. Park,
M. Y. Kim, and W. S. Shin.
2000.
Detection of human herpesvirus 6 variant A in peripheral blood mononuclear cells from multiple sclerosis patients.
Eur. Neurol.
43:170-173[CrossRef][Medline].
|
| 24.
|
Knox, K. K., and D. R. Carrigan.
1996.
Active HHV-6 infection in the lymph nodes of HIV-infected patients: in vitro evidence that HHV-6 can break HIV latency.
J. Acquir. Immune Defic. Syndr. Hum. Retrovir.
11:370-378[Medline].
|
| 25.
|
Li, C.,
J. M. Goodrich, and X. Yang.
1997.
Interferon-gamma (IFN-gamma) regulates production of IL-10 and IL-12 in human herpesvirus-6 (HHV-6)-infected monocyte/macrophage lineage.
Clin. Exp. Immunol.
109:421-425[CrossRef][Medline].
|
| 26.
|
Lusso, P.,
A. De Maria,
M. Malnati,
F. Lori,
S. E. DeRocco,
M. Baseler, and R. C. Gallo.
1991.
Induction of CD4 and susceptibility to HIV-1 infection in human CD8+ T lymphocytes by human herpesvirus 6.
Nature
349:533-535[CrossRef][Medline].
|
| 27.
|
Lusso, P.,
B. Ensoli,
P. D. Markham,
D. V. Ablashi,
S. Z. Salahuddin,
E. Tschachler,
F. Wong-Staal, and R. C. Gallo.
1989.
Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV- 6.
Nature
337:370-373[CrossRef][Medline].
|
| 28.
|
Okamura, H.,
H. Tsutsui,
S. Kashiwamura,
T. Yoshimoto, and K. Nakanishi.
1998.
Interleukin-18: a novel cytokine that augments both innate and acquired immunity.
Adv. Immunol.
70:281-312[Medline].
|
| 29.
|
Ongradi, J.,
C. Rajda,
C. L. Marodi,
A. Csiszar, and L. Vecsei.
1999.
A pilot study on the antibodies to HHV-6 variants and HHV-7 in CSF of MS patients.
J. Neurovirol.
5:529-532[Medline].
|
| 30.
|
Pellett, P. E.,
D. Sanchez-Martinez,
G. Dominguez,
J. B. Black,
E. Anton,
C. Greenamoyer, and T. R. Dambaugh.
1993.
A strongly immunoreactive virion protein of human herpesvirus 6 variant B strain Z29: identification and characterization of the gene and mapping of a variant-specific monoclonal antibody reactive epitope.
Virology
195:521-531[CrossRef][Medline].
|
| 31.
|
Pirhonen, J.,
T. Sareneva,
M. Kurimoto,
I. Julkunen, and S. Matikainen.
1999.
Virus infection activates IL-1 beta and IL-18 production in human macrophages by a caspase-1-dependent pathway.
J. Immunol.
162:7322-7329[Abstract/Free Full Text].
|
| 32.
|
Ploegh, H. L.
1998.
Viral strategies of immune evasion.
Science
280:248-253[Abstract/Free Full Text].
|
| 33.
|
Rotola, A.,
E. Caselli,
E. Cassai,
M. R. Tola,
E. Granieri, and D. D. Luca.
2000.
Novel human herpesviruses and multiple sclerosis.
J. Neurovirol.
6(Suppl. 2):S88-S91.
|
| 34.
|
Salahuddin, S. Z.,
D. V. Ablashi,
P. D. Markham,
S. F. Josephs,
S. Sturzenegger,
M. Kaplan,
G. Halligan,
P. Biberfeld,
F. Wong-Staal,
B. Kramarsky, et al.
1986.
Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders.
Science
234:596-601[Abstract/Free Full Text].
|
| 35.
|
Sanders, V. J.,
S. Felisan,
A. Waddell, and W. W. Tourtellotte.
1996.
Detection of herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction.
J. Neurovirol.
2:249-258[Medline].
|
| 36.
|
Santoro, F.,
P. E. Kennedy,
G. Locatelli,
M. S. Malnati,
E. A. Berger, and P. Lusso.
1999.
CD46 is a cellular receptor for human herpesvirus 6.
Cell
99:817-827[CrossRef][Medline].
|
| 37.
|
Secchiero, P.,
D. Zella,
R. W. Crowley,
R. C. Gallo, and P. Lusso.
1995.
Quantitative PCR for human herpesviruses 6 and 7.
J. Clin. Microbiol.
33:2124-2130[Abstract].
|
| 38.
|
Shapiro, L.,
A. J. Puren,
H. A. Barton,
D. Novick,
R. L. Peskind,
R. Shenkar,
Y. Gu,
M. S. Su, and C. A. Dinarello.
1998.
Interleukin 18 stimulates HIV type 1 in monocytic cells.
Proc. Natl. Acad. Sci. USA
95:12550-12555[Abstract/Free Full Text].
|
| 39.
|
Singh, N., and D. L. Paterson.
2000.
Encephalitis caused by human herpesvirus-6 in transplant recipients: relevance of a novel neurotropic virus.
Transplantation
69:2474-2479[CrossRef][Medline].
|
| 40.
|
Soldan, S. S.,
R. Berti,
N. Salem,
P. Secchiero,
L. Flamand,
P. A. Calabresi,
M. B. Brennan,
H. W. Maloni,
H. F. McFarland,
H. C. Lin,
M. Patnaik, and S. Jacobson.
1997.
Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA.
Nat. Med.
3:1394-1397[CrossRef][Medline].
|
| 41.
|
Soldan, S. S., and S. Jacobson.
2001.
Role of viruses in etiology and pathogenesis of multiple sclerosis, p. 511-552.
In
M. Buchmeier, and I. Campbell (ed.), Advances in virus research. Academic Press, Inc., New York, N.Y.
|
| 42.
|
Soldan, S. S.,
T. P. Leist,
K. N. Juhng,
H. F. McFarland, and S. Jacobson.
2000.
Increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients.
Ann. Neurol.
47:306-313[CrossRef][Medline].
|
| 43.
|
Tatsuo, H.,
N. Ono,
K. Tanaka, and Y. Yanagi.
2000.
SLAM (CDw150) is a cellular receptor for measles virus.
Nature
406:893-897[CrossRef][Medline].
|
| 44.
|
Thomson, A. W.
1998.
The cytokine handbook, 3rd ed.
Academic Press, San Diego, Calif.
|
| 45.
|
Waal Malefyt, R., and K. Moore.
1998.
Interleukin-10, p. 333-364.
In
A. W. Thomson (ed.), The cytokine handbook, 3rd ed. Academic Press, San Diego, Calif.
|
| 46.
|
Wesselingh, S. L.,
C. Power,
J. D. Glass,
W. R. Tyor,
J. C. McArthur,
J. M. Farber,
J. W. Griffin, and D. E. Griffin.
1993.
Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia.
Ann. Neurol.
33:576-582[CrossRef][Medline].
|
| 47.
|
Yamanishi, K.,
T. Okuno,
K. Shiraki,
M. Takahashi,
T. Kondo,
Y. Asano, and T. Kurata.
1988.
Identification of human herpesvirus-6 as a causal agent for exanthem subitum.
Lancet
i:1065-1067.
|
| 48.
|
Yoshikawa, T., and Y. Asano.
2000.
Central nervous system complications in human herpesvirus-6 infection.
Brain Dev.
22:307-314[CrossRef][Medline].
|
| 49.
|
Zou, P.,
Y. Isegawa,
K. Nakano,
M. Haque,
Y. Horiguchi, and K. Yamanishi.
1999.
Human herpesvirus 6 open reading frame U83 encodes a functional chemokine.
J. Virol.
73:5926-5933[Abstract/Free Full Text].
|
Journal of Virology, December 2001, p. 11641-11650, Vol. 75, No. 23
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.23.11641-11650.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Yeo, W. M., Isegawa, Y., Chow, V. T. K.
(2008). The U95 Protein of Human Herpesvirus 6B Interacts with Human GRIM-19: Silencing of U95 Expression Reduces Viral Load and Abrogates Loss of Mitochondrial Membrane Potential. J. Virol.
82: 1011-1020
[Abstract]
[Full Text]
-
Mlechkovich, G., Frenkel, N.
(2007). Human Herpesvirus 6A (HHV-6A) and HHV-6B Alter E2F1/Rb Pathways and E2F1 Localization and Cause Cell Cycle Arrest in Infected T Cells. J. Virol.
81: 13499-13508
[Abstract]
[Full Text]
-
Cermelli, C., Cenacchi, V., Beretti, F., Pezzini, F., Luca, D. D., Blasi, E.
(2006). Human herpesvirus-6 dysregulates monocyte-mediated anticryptococcal defences. J Med Microbiol
55: 695-702
[Abstract]
[Full Text]
-
De Bolle, L., Naesens, L., De Clercq, E.
(2005). Update on Human Herpesvirus 6 Biology, Clinical Features, and Therapy. Clin. Microbiol. Rev.
18: 217-245
[Abstract]
[Full Text]
-
McLaren, P. J., Mayne, M., Rosser, S., Moffatt, T., Becker, K. G., Plummer, F. A., Fowke, K. R.
(2004). Antigen-Specific Gene Expression Profiles of Peripheral Blood Mononuclear Cells Do Not Reflect Those of T-Lymphocyte Subsets. CVI
11: 977-982
[Abstract]
[Full Text]
-
Niiya, H., Azuma, T., Jin, L., Uchida, N., Inoue, A., Hasegawa, H., Fujita, S., Tohyama, M., Hashimoto, K., Yasukawa, M.
(2004). Transcriptional downregulation of DC-SIGN in human herpesvirus 6-infected dendritic cells. J. Gen. Virol.
85: 2639-2642
[Abstract]
[Full Text]
-
Dietrich, J., Blumberg, B. M., Roshal, M., Baker, J. V., Hurley, S. D., Mayer-Proschel, M., Mock, D. J.
(2004). Infection with an Endemic Human Herpesvirus Disrupts Critical Glial Precursor Cell Properties. J. Neurosci.
24: 4875-4883
[Abstract]
[Full Text]
-
ERMAK, G., CHEADLE, C., BECKER, K. G., HARRIS, C. D., DAVIES, K. J. A.
(2004). DSCR1(Adapt78) modulates expression of SOD1. FASEB J.
18: 62-69
[Abstract]
[Full Text]
-
Smith, A., Santoro, F., Di Lullo, G., Dagna, L., Verani, A., Lusso, P.
(2003). Selective suppression of IL-12 production by human herpesvirus 6. Blood
102: 2877-2884
[Abstract]
[Full Text]
-
Mi, Q.-S., Ly, D., Lamhamedi-Cherradi, S.-E., Salojin, K. V., Zhou, L., Grattan, M., Meagher, C., Zucker, P., Chen, Y. H., Nagle, J., Taub, D., Delovitch, T. L.
(2003). Blockade of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Exacerbates Type 1 Diabetes in NOD Mice. Diabetes
52: 1967-1975
[Abstract]
[Full Text]
-
Cheadle, C., Vawter, M. P., Freed, W. J., Becker, K. G.
(2003). Analysis of Microarray Data Using Z Score Transformation. J. Mol. Diagn.
5: 73-81
[Abstract]
[Full Text]
-
van Huizen, R., Martindale, J. L., Gorospe, M., Holbrook, N. J.
(2003). P58IPK, a Novel Endoplasmic Reticulum Stress-inducible Protein and Potential Negative Regulator of eIF2alpha Signaling. J. Biol. Chem.
278: 15558-15564
[Abstract]
[Full Text]
-
Gracie, J. A., Robertson, S. E., McInnes, I. B.
(2003). Interleukin-18. J. Leukoc. Biol.
73: 213-224
[Abstract]
[Full Text]
-
Dockrell, D.H.
(2003). Human herpesvirus 6: molecular biology and clinical features. J Med Microbiol
52: 5-18
[Abstract]
[Full Text]
-
Jones, J. O., Arvin, A. M.
(2002). Microarray Analysis of Host Cell Gene Transcription in Response to Varicella-Zoster Virus Infection of Human T Cells and Fibroblasts In Vitro and SCIDhu Skin Xenografts In Vivo. J. Virol.
77: 1268-1280
[Abstract]
[Full Text]
-
Fan, J., Yang, X., Wang, W., Wood, W. H. III, Becker, K. G., Gorospe, M.
(2002). Global analysis of stress-regulated mRNA turnover by using cDNA arrays. Proc. Natl. Acad. Sci. USA
99: 10611-10616
[Abstract]
[Full Text]